A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2)
← catalyst calendarNCT06976203 · readout in 754 d
Sponsored by Bristol-Myers Squibb (industry) · BMY — their whole pipeline →.
Phase
Phase 3
Status
Recruiting
Study type
Interventional
Design
Randomized · Double · Treatment
Enrollment
586estimated
Sites
126
Countries
Argentina, Australia, Brazil +14
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-07-21 | actual | When the study began enrolling |
| Primary completion | 2028-09-11 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2029-02-23 | estimated | The whole study's end, after follow-up |
| First posted | 2025-05-16 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-12 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Alzheimer's Disease
Interventions
- Drug: KarXT — also filed as BMS-986510
- Drug: KarX-EC — also filed as BMS-986519
- Other: Placebo
Primary outcomes
what the primary-completion date above is the date OFChange from baseline in Alzheimer's Disease Assessment Scale-Cognitive Subscale 11 (ADAS-Cog11)
measured At week 24
Clinician's Interview-Based Impression Plus Caregiver Input (CIBIC+)
measured At week 24
Permalink · BMY's whole pipeline · Catalyst calendar · Every registered study · What changed